Ripple kopen? Dit zijn de mogelijkheden

Galapagos Aandeel

140,75EUR -0,95EUR -0,67%
<
Bedrijf
Kalender
Profiel
>
<
Gerelateerd
Obligaties
>

Galapagos - Profiel

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Aandeelhouder

Eigenaar in %
Gilead Sciences, Inc.12,33
Van Herk Investments BV10,57
Johnson & Johnson7,61
Gestion Deelnemingen V BV7,40
Wellington Management Co. LLP6,25
Capital Research & Management Co. (World Investors)4,75
Fidelity Management & Research Co.4,64
Delta Lloyd Asset Management NV3,85
Baker Bros. Advisors LP3,85
Schroder Investment Management Ltd.3,67
The Vanguard Group, Inc.2,28
Invesco Advisers, Inc.1,80
GlaxoSmithKline Plc1,68
Gilder, Gagnon, Howe & Co. LLC1,38
T. Rowe Price International Ltd.1,20

Adres

Industriepark Mechelen Noord, 2800 Mechelen
Postbus:
Telefoon: 3215342900
Fax: 3215342901
Internet: http://www.glpg.com

Management

Raj B. Parekh, PhD
Chairman
Andre Hoekema, PhD
Chief Business Officer
Onno van de Stolpe, PhD
Chief Executive Officer & Executive Director
Walid Abi-Saab, MD
Chief Medical Officer
Bart Filius, MBA
Chief Operating & Financial Officer
Piet Wigerinck, PhD
Chief Scientific Officer
Paul van der Horst
Director-Business Development & IR
Evelyn Fox
Director-Communications & Head-Media Relations
Sofie Van Gijsel
Director-Investor Relations
Peter Guenter
Independent Director
Mary Kerr PhD, MBA
Independent Non-Executive Director
Howard Mitchell Rowe, PhD
Independent Non-Executive Director
Katrine S. Bosley
Independent Non-Executive Director
Xavier Marie Bernard Cecile Maes
Secretary
Carmen Vroonen
Senior Director-Communications & Public Affairs
Elizabeth Goodwin
VP-Corporate Communications & Investor Relations

Invoer toevoegen